Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 739-uterine-and-adnexa-procedures-for-non-ovarian-and-non-adnexal-malignancy-with-mcc
    Ask Trek AI about this page

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    DRG 739 addresses inpatient admissions for uterine and adnexa procedures for non-ovarian and non-adnexal malignancy with a Major Complication or Comorbidity, defining a higher-severity payment category. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group increases the Medicare Severity Diagnosis-Related Group payment to reflect greater resource consumption and complexity of care.

    Customize your policy alerts

    Sign up for drg 739 policy alerts

    Get alerted when payer policies referencing 739 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 739 Overview

    DRG 739 covers inpatient admissions for uterine and adnexa procedures performed for non-ovarian and non-adnexal malignancy when a Major Complication or Comorbidity is present. This Diagnosis-Related Group captures higher resource use due to the complexity of surgical management and the presence of serious comorbid conditions. It matters for Medicare payment because cases assigned to this Diagnosis-Related Group typically receive higher reimbursement to account for increased length of stay, intensive perioperative care, and additional diagnostic or therapeutic interventions. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus affect inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative management and surgical technique trials: Studies compare minimally invasive (laparoscopic or robotic) versus open abdominal approaches specifically in patients undergoing hysterectomy and adnexal procedures for non-ovarian, non-adnexal uterine malignancies who also have major comorbidities (eg, advanced cardiac disease, morbid obesity, or significant pulmonary disease). These trials evaluate intraoperative metrics (blood loss, operative time), 30-day complication rates, and impacts on length of stay and intensive care utilization. Results inform surgeons and hospital administrators about which approaches reduce perioperative morbidity and resource use in a high-risk MCC population, directly affecting case-mix-adjusted reimbursement and cost planning.
    • Comparative effectiveness and adjuvant therapy sequencing studies: Research examines outcomes of different adjuvant therapy timing and combinations (eg, early versus delayed radiation or systemic therapy sequencing) after definitive uterine/adnexal procedures in patients with high-risk pathologic features and major complications or comorbidities. These studies enroll patients with histologic subtypes and staging consistent with non-ovarian/non-adnexal uterine malignancy and track recurrence-free survival, treatment-related toxicity, readmissions, and cumulative inpatient utilization over 1–3 years. Evidence from these trials helps oncologists and payers weigh trade-offs between short-term inpatient resource intensity and long-term outcomes, guiding coverage policies for post-operative care pathways and bundled payment models.
    • Post-discharge outcomes, readmission prevention, and care coordination trials: Pragmatic studies test interventions such as structured discharge protocols, high-intensity post-discharge nursing follow-up, or remote monitoring for patients with major comorbidities who underwent uterine/adnexal surgery for non-ovarian malignancy. These trials target the early post-discharge window when this MCC population is at elevated risk for complications (wound infections, thromboembolism, or decompensation of chronic conditions), measuring 30- and 90-day readmission rates, emergency department visits, and total post-acute care costs. Findings are highly relevant to hospital quality teams and payers aiming to reduce preventable readmissions and to optimize care transitions that affect reimbursement under value-based payment arrangements.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    744-D-C-CONIZATION-LAPAROSCOPY-AND-TUBAL-INTERRUPTION-WITH-CC-MCC

    D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.